FAQs about delivery changes

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

898.63 -19.59 (-2.13%)
Streaming Delayed Price Updated: 3:20 PM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
From argenx SE
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For argenx ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring argenx Through Analyst Insights ↗
 
Via Benzinga
News headline image
What 25 Analyst Ratings Have To Say About argenx ↗
 
Via Benzinga
News headline image
The Analyst Verdict: argenx In The Eyes Of 27 Experts ↗
 
Via Benzinga
News headline image
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
From argenx SE
Via GlobeNewswire
News headline image
Biotech Stocks : Are You A Trader Or A Longer Term Investor? ↗
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. 
Via Talk Markets
News headline image
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
News headline image
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB ↗
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
Via Benzinga
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
From argenx SE
Via GlobeNewswire
News headline image
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
News headline image
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
News headline image
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
From argenx SE
Via GlobeNewswire
News headline image
Why Is European Drugmaker Argenx Stock Trading Higher On Monday? ↗
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030. 
Via Benzinga
News headline image
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval ↗
This is the second approval for the biotech company's drug, Vyvgart Hytrulo. 
Via Investor's Business Daily
News headline image
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article